Infinity Pharmaceuticals Provides Update for Eganelisib in Patients with Metastatic Urothelial Cancer
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today provided an update on MARIO-275, the Companys randomized, placebo controlled Phase 2 study evaluating the benefit of adding eganelisib to nivolumab (Opdivo) in platinum-refractory, I/O nave patients with advanced, metastatic urothelial cancer (mUC) over nivolumab monotherapy which is approved in this setting.
- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today provided an update on MARIO-275, the Companys randomized, placebo controlled Phase 2 study evaluating the benefit of adding eganelisib to nivolumab (Opdivo) in platinum-refractory, I/O nave patients with advanced, metastatic urothelial cancer (mUC) over nivolumab monotherapy which is approved in this setting.
- The MARIO-275 study provided Infinity with important insights to shape the future of eganelisib in urothelial cancer, said Adelene Perkins, Chief Executive Officer and Chair of Infinity Pharmaceuticals.
- We are leveraging the clinical and translational learnings from MARIO-275 in planning a new, registration-enabling study of eganelisib in patients with advanced urothelial cancer.
- MARIO-275 is a global, randomized, placebo-controlled combination study of eganelisib combined with Opdivo in I/O nave urothelial cancer.